aln-ang3
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 27, 2024 (NCT06452771)
Timeline
Indications
Mechanism of action
- Angiopoietin-related protein 3ANTISENSE INHIBITOR
ANGPTL3 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07271186 | Phase 2 | Dec 9, 2025 | Regeneron |
| NCT06452771 | Phase 1 | Jun 27, 2024 | Regeneron |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1